Metabolic dysfunctions in pancreatic ductal adenocarcinoma: Pathogenic mechanisms and therapeutic implications.
Pancreatic ductal adenocarcinoma (PDAC) remains a highly aggressive malignancy characterized by a dismal prognosis and profound resistance to conventional therapies. Emerging evidence highlights systemic metabolic dysfunctions including obesity, dyslipidemia, type 2 diabetes mellitus (T2DM), and non-alcoholic fatty pan...